Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2023-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It is issued by an accounting firm (容诚会计师事务所) and addresses the shareholders of 安徽安科生物工程（集团）股份有限公司. The document states it is a verification report on the company's 2022 annual report regarding the use and storage of raised funds, prepared according to regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The document contains an auditor's opinion and verification conclusion, indicating it is a standalone audit or assurance report related to the use of capital raised by the company, not the full annual report itself. The document length is short (1417 characters), but it contains substantive auditor verification content, not just an announcement or certification. Therefore, it fits best under Audit Report / Information (AR) category, which covers standalone audit reports and applied accounting principles, excluding full annual reports. FY 2022
2023-03-27 Chinese
独立董事2022年度述职报告（耿小平）
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. It outlines the director's activities, attendance at board meetings, independent opinions, investigations, audit participation, investor protection efforts, committee work, and training during the 2022 fiscal year. The content focuses on governance, oversight, and compliance with laws and regulations, typical of a management or board-related report. It is not a full annual report (10-K), audit report, or earnings release, but rather a specific report on the independent director's duties and activities for the year. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports.
2023-03-27 Chinese
2022年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled '审计报告' which translates to 'Audit Report'. It is issued by a certified accounting firm (容诚会计师事务所) and includes detailed audit opinions, audit basis, key audit matters, and responsibilities of management and auditors. The content includes detailed financial statements such as consolidated balance sheets, profit and loss statements, cash flow statements, and notes to the financial statements. The document covers the fiscal year ending December 31, 2022, and contains substantive financial data and analysis. This matches the definition of an Audit Report / Information (AR) filing, which is a standalone audit report including applied accounting principles and audit results, distinct from a full Annual Report (10-K). The document is lengthy (15,000 characters) and contains the full audit report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2022
2023-03-27 Chinese
2022年度内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制鉴证报告' which translates to 'Internal Control Assurance Report'. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls related to the financial reporting of Anhui Anke Bioengineering (Group) Co., Ltd. for the year ended December 31, 2022. The document includes the auditor's responsibilities, limitations of internal control, and an assurance conclusion on the effectiveness of internal controls. It is not a full annual report (10-K), nor is it a management report or earnings release. It is a standalone audit-related assurance report focusing on internal control over financial reporting, which fits the definition of an Audit Report / Information (AR). The document length is short (1365 characters), but it contains the actual assurance report, not just an announcement or certification letter. Therefore, the correct classification is AR with high confidence. FY 2022
2023-03-27 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is an announcement of resolutions passed at the second meeting of the eighth Supervisory Board of Anhui Anke Biotechnology (Group) Co., Ltd. It includes approvals of the 2022 Supervisory Board Work Report, 2022 Financial Final Accounts Report, 2022 Annual Report and its summary, 2022 Profit Distribution Plan, 2022 Internal Control Self-Evaluation Report, and other related proposals. The document states these reports and proposals will be submitted to the 2022 Annual General Meeting for approval. The document is relatively short (3280 characters) and serves as a formal announcement of meeting resolutions rather than the full reports themselves. It also references that detailed content is disclosed on the official disclosure website. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions and report approvals, not the full annual report or financial statements themselves.
2023-03-27 Chinese
独立董事2022年度述职报告（张本山）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Anke Biotechnology (Group) Co., Ltd. for the year 2022. It covers the director's attendance at board and shareholder meetings, independent opinions on various company matters including share repurchases, audit firm reappointment, internal controls, related party transactions, employee stock incentive plans, board nominations, and other governance activities. The content focuses on the independent director's duties, opinions, and oversight activities throughout the year, which is typical of an independent director's annual report or statement. It is not a full annual report (10-K), audit report, earnings release, or other financial report. It is also not a simple announcement or certification but a substantive report on the independent director's work and opinions for the year. This fits best with the category of Board/Management Information (MANG), which includes announcements or reports related to board members and senior management activities and statements. The document length (6694 characters) and detailed content support this classification with high confidence.
2023-03-27 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.